MONTREAL, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company’s President and CEO, Paul Lévesque will be presenting at two investor conferences in September. Members of the Theratechnologies management team will also be available for one-on-one meetings throughout the conferences.
| H.C. Wainwright 26th Annual Global Investment Conference | |
| Date: | September 9-11, 2024 |
| Location: | Lotte New York Palace Hotel |
| Presentation Details: | Virtual presentation accessible online to conference attendees on the morning of Monday, September 9, 2024 |
| 2024 Cantor Global Healthcare Conference | |
| Date: | September 17-19, 2024 |
| Location: | InterContinental Barclay Hotel, New York |
| Presentation Details: | Fireside chat on Wednesday, September 18 at 8:00-8:30 a.m. ET in Track 4, Empire Ballroom 1 |
About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on LinkedIn and X (formerly Twitter).
Contacts:
Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-438-315-6608
Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
This email address is being protected from spambots. You need JavaScript enabled to view it.
1-514-336-7800
| Last Trade: | US$1.82 |
| Daily Change: | 0.02 1.11 |
| Daily Volume: | 185,380 |
| Market Cap: | US$83.680M |
December 18, 2024 December 10, 2024 December 04, 2024 December 03, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
